This study looks at whether adding intismeran autogene to pembrolizumab helps people with non-small cell lung cancer (NSCLC) stay cancer-free longer after surgery. The goal is to see if this combination can prevent the cancer from coming back in those whose tumors did not respond completely to earlier treatment. Researchers hope to find a better way to help patients after surgery.
The trial's ID number is NCT06623422. This is a Phase 3 study, which means it is looking at how well the treatments work and how safe they are. It is regulated by the FDA, and the study hopes to include about 680 participants.
Who can join
This trial is open to adults aged 18 and older, both men and women. Participants must have a specific type of lung cancer that can be surgically removed and have not had certain types of previous treatments. Some health conditions may affect eligibility. The trial team will confirm who can join based on detailed health criteria.
Condition
Carcinoma, Non-Small-Cell Lung
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly placed into two groups. One group will receive pembrolizumab along with intismeran autogene after surgery. The other group will receive pembrolizumab with a placebo, which looks like the treatment but has no active medicine. All participants will first receive pembrolizumab and other chemotherapy before surgery.
Where
This trial is enrolling at 50 locations. Recruiting sites are listed first.
Banner MD Anderson Cancer Center ( Site 0181)
Gilbert, Arizona
Recruiting
Banner MD Anderson Cancer Center at North Colorado Medical Center ( Site 0207)
Greeley, Colorado
Recruiting
Beacon Cancer Care ( Site 0127)
Post Falls, Idaho
Recruiting
Centura Health - St. Anthony North Health Campus ( Site 0189)
Westminster, Colorado
Recruiting
Dana Farber Cancer Hospital ( Site 0155)
Boston, Massachusetts
Recruiting
Eastern CT Hematology & Oncology Associates ( Site 0202)
Norwich, Connecticut
Recruiting
Elliston Place Medical Oncology & Hematology ( Site 0215)
Nashville, Tennessee
Recruiting
Hematology-Oncology Associates of CNY ( Site 0164)
Chief of Thoracic Surgery and Director of the Lung Cancer Program at West Virginia University Cancer Institute. Treats lung cancer and esophageal cancer.
Treats pancreatic cancer, lung cancer and colorectal cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Led the National Lung Screening Trial. Treats lung cancer. Other doctors who help with cancer care, like gastroenterologists, dermatologists, and endocrinologists. Recognized at state, national or international level.